Issue highlights:
- Catalysed by COVID-19, IR societies say hybrid conferences are here to stay
- Portal vein embolization with NBCA promotes greater liver growth than PVA, BestFLR trial finds
- Starting to close the door on the paclitaxel controversy: TCT late-breaking trials
- Commentary: Radioembolization with Y-90 now “a versatile treatment option” for HCC patients of all stages—Robert Lewandowski
- Profile: Adam Hatzidakis
